Current estimates
suggest that during
the first 10 years

of biosimilar availability, consumers could
save as much as $250 billion.

The Biosimilars Council

is a division of the Association for Accessible Medicines, formerly known as GPhA, who works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars.

Interested in getting involved?

The Biosimilars Council routinely participates in and hosts events to promote knowledge around the advancement of biosimilars in the United States.

See below for information on our annual conference and a link to download our Handbook.

What are biosimilars?

Put simply, biosimilars are biologic medicines that are highly similar to a corresponding brand biologic. Biosimilars offer a safe, effective, and affordable alternative for patients. They are approved by the U.S. Food and Drug Administration (FDA) and improve patient access to life-saving medicines. 


Reports, videos, news sources, and more. Take some time to learn all about biosimilars and the benefits they offer US consumers.


Take a minute and learn all about biosimilars and our industry in an easy to digest format. The best part? It’s free.


We are always on the road advocating for biosimilars and invite you to join us. Check out the details for our next event and bring your friends.

Keep up-to-date with the latest
news and information on biosimilars
by signing up for our mailing list.


Press Releases


Join Our Mailing List

Receive breaking news, progress updates on regulations at both the state and federal level, and information on the future of biosimilars in the United States.
  • This field is for validation purposes and should be left unchanged.